Our Publications
We pride ourselves on making a meaningful contribution to the global quest to defeat cancer. Explore the publications and conference abstracts on this page to learn more about the research that supports our novel science.
Abstract
A phase 1/2 study to evaluate the safety, tolerability, and preliminary efficacy of GP-2250 in combination with gemcitabine for advanced or metastatic pancreatic adenocarcinoma.
ASCO Gastrointestinal Cancers Symposium, Journal of Clinical Oncology 2022;40:4_suppl, TPS620-TPS620
A. Kasi, J. L. Iglesias.
Abstract
Metabolism-based GP-2250 in combination with gemcitabine as a novel approach to pancreatic cancer: A mouse xenograft study- in vitro and in vivo. MBC Cancer
ASCO Annual Meetings 2020, Chicago (Abstract: Journal of Clinical Oncology 38, no. 15_suppl. DOI: 10.1200/JCO.2020.38.15_suppl.e16750
C. Braumann, M. Buchholz, B. Majchrzak – Stiller, S. Hahn, W. Uhl, A. Kasi, T. Mueller.)
Abstract
Pancreatic Tumor Remission in PDX-Models by Treatment with Gemcitabine in Combination with the Oxathiazine GP-2250 promising anti-neoplastic agent in malignant pancreatic carcinoma- in vitro and in vivo. MBC Cancer
German Cancer Congress, February 2020, Berlin, Germany (Abstract: Oncology Res Treat 2020; 43 (supply 1): 1-265, abstract 455, page 58 DOI: 10.1159/000506491)
B. Majchrzak-Stiller, M. Buchholz, S. Hahn, C. Braumann, W. Uhl.
Publication
Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma- in vitro and in vivo.
2017, 17, 1-13. DOI: 10.1186/s12885-017-3204-x
M. Buchholz, B. Majchrzak-Stiller, S. Hahn, D. Vangala, R. W. Pfirrmann, W. Uhl, C. Braumann and A. M. Chromik.
Abstract
Innovative substance 2250, a derivative of taurultam, shows anti-neoplastic effects in malignant pancreatic carcinoma in vitro and in vivo
German Cancer Congress, February 2016, Berlin, Germany (Abstract: Oncology Res Treat 2016; 39 (supply 1):1–175, abstract ID 0144, DOI: 10.1159/000444354)
M. Buchholz, B. Majchrzak-Stiller, S. Hahn, R.W. Pfirrmann, A.M. Chromik, W. Uhl.
Participate
Become a clinician or patient participant.
Are you a clinician or patient who is interested in learning about or participating in our active studies?
Science
Discover our novel mechanism of action.
Our mechanism of action suppresses cancers by disrupting their energy metabolism, bringing about cancer cell death.